Research
Hormonal
Tirzepatide provides cardiovascular protection by reducing major adverse cardiovascular events (MACE) and improving cardiovascular risk scores in patients with type 2 diabetes and obesity.
Tirzepatide not only helps with weight and blood sugar but also lowers your long-term risk of heart attack and stroke. It improves blood pressure and cholesterol, contributing to overall heart health.
StrongSupportsHIGH confidence
Tirzepatid ve srovnání s inzulinem glargin nezvyšoval kardiovaskulární riziko vyjádřené dosažením endpointu MACE4... zaznamenali pacienti léčení všemi dávkami tirzepatidu významný pokles kardiovaskulárního rizikového skóre proti placebové skupině.
Why this rating
Based on Phase 3 trials (SURPASS 4, SURMOUNT-1) and ongoing SURPASS-CVOT.
Source
Tirzepatide - a promising medication for cardiovascular protection and treatment of Type 2 diabetes and obesity
Pavlína Piťhová · Vnitřní lékařství · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →